Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ImVisioN Therapeutics AG

http://www.imvision-therapeutics.com

Latest From ImVisioN Therapeutics AG

Circassia Itching To Transform Allergy Sector

U.K. biotech Circassia has the first potential cat allergy vaccine to reach advanced clinical studies in Europe and the U.S., funded by a large round of VC financing completed in 2011. Its allergen-free technology could revolutionize the treatment of allergies.

BioPharmaceutical Europe

Private investment round-up: September 2008

Despite the unpredictability and fluctuation of the world's financial markets last month, a surprising number of pharmaceutical companies secured private investments, and the total amount raised rose, a Scripanalysis has found.

Cancer Orthopedics

Recent Financings of Private Companies (10/2008)

Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.

ImVisioN GMBH

ImVisioN GMBH's focus is allergy immunotherapy, and it is using its platform technologies to create a pipeline of treatments for major allergies. ILIT, ImVisioN's delivery technology, allows administration of the allergen directly into the lymph nodes, which contain high concentrations of antigen-presenting cells. Its MAT technology is designed to maximize the immune protective response from T helper cell type 1 and minimize the Th2-mediated inflammatory responses.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Other Names / Subsidiaries
    • ImVisioN GmbH
UsernamePublicRestriction

Register